Live webcast on Thursday, April
4th at 4:10 PM
ET
HOUSTON, March 28, 2024 /PRNewswire/ -- Moleculin
Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the
Company), a clinical stage pharmaceutical company with a broad
portfolio of drug candidates targeting hard-to-treat tumors and
viruses, today announced Walter
Klemp, President and Chief Executive Officer of
Moleculin will present at the MedInvest Biotech & Pharma
Investor Conference behind held in New York City, NY on Thursday, April 4, 2024 at 4:10 PM ET.
In addition to the presentation, management will be available to
participate in one-on-one meetings with qualified members of the
investor community who are registered to attend the conference. For
more information about the event, please visit the
conference website.
A live webcast of the event will be available on the Events page
in the Investors section of the Company's website
(moleculin.com).
About Moleculin Biotech, Inc.
Moleculin Biotech, Inc. is a clinical stage pharmaceutical
company with a growing pipeline, including Phase 2 clinical
programs, for hard-to-treat tumors and viruses. The Company's lead
program, Annamycin is a next-generation anthracycline designed to
avoid multidrug resistance mechanisms with little to no
cardiotoxicity. Annamycin is currently in development for the
treatment of relapsed or refractory acute myeloid leukemia (AML)
and soft tissue sarcoma (STS) lung metastases.
Additionally, the Company is developing WP1066, an
Immune/Transcription Modulator capable of inhibiting p-STAT3 and
other oncogenic transcription factors while also stimulating a
natural immune response, targeting brain tumors, pancreatic and
other cancers, and WP1220, an analog to WP1066, for the topical
treatment of cutaneous T-cell lymphoma. Moleculin is also engaged
in the development of a portfolio of antimetabolites, including
WP1122 for the potential treatment of viruses, as well as cancer
indications including brain tumors, pancreatic and other
cancers.
For more information about the Company, please
visit www.moleculin.com and connect on Twitter, LinkedIn
and Facebook.
Investor Contact:
JTC Team, LLC
Jenene Thomas
(833) 475-8247
MBRX@jtcir.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/moleculin-to-present-at-the-medinvest-biotech--pharma-investor-conference-302102695.html
SOURCE Moleculin Biotech, Inc.